Vorinostat

Generic Name: Vorinostat

Brand Names: Zolinza

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₀N_₂O_₃

CAS Number: 149647-78-9

Unique Ingredient Identifier: 58IFB293JI

Background: Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...

Indication: 用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。

Associated Conditions: Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma

Associated Therapies: -

Clinical Trials

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

Phase 2

Completed

Conditions: Recurrent Oral Cavity Adenoid Cystic Carcinoma
Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Stage III Major Salivary Gland Cancer AJCC v7
Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Recurrent Salivary Gland Carcinoma
Salivary Gland Adenoid Cystic Carcinoma
Stage IVB Major Salivary Gland Cancer AJCC v7
Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Tongue Carcinoma
Stage IVA Major Salivary Gland Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Vorinostat

First Posted Date: 2010-08-05

Last Posted Date: 2020-08-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT01175980

Locations: 🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 9 locations

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Prostate Cancer

Interventions: Drug: vorinostat
Drug: temsirolimus
Other: laboratory biomarker analysis
Procedure: positron emission tomography/computed tomography

First Posted Date: 2010-08-03

Last Posted Date: 2022-10-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 13

Registration Number: NCT01174199

Locations: 🇺🇸
The Sydney Kimmel Comprehensive Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: ridaforolimus
Drug: vorinostat
Procedure: biopsy
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2010-07-26

Last Posted Date: 2021-02-21

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 16

Registration Number: NCT01169532

Locations: 🇺🇸
Fox Chase Cancer Center, Rockledge, Pennsylvania, United States

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Not Applicable

Completed

Conditions: Recurrent Breast Cancer
Stage IV Breast Cancer
Male Breast Cancer

Interventions: Drug: vorinostat
Other: laboratory biomarker analysis
Procedure: biopsy
Radiation: F-18 16 alpha-fluoroestradiol
Procedure: positron emission tomography
Drug: anastrozole
Drug: letrozole
Drug: exemestane
Genetic: gene expression analysis

First Posted Date: 2010-06-30

Last Posted Date: 2019-09-06

Lead Sponsor: University of Washington

Target Recruit Count: 8

Registration Number: NCT01153672

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Vorinostat

First Posted Date: 2010-05-26

Last Posted Date: 2017-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT01130506

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States